Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 243

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

ONECUT2 is a driver of neuroendocrine prostate cancer

Open access
Guo, Haiyang, Ci, Xinpei, Ahmed, Musaddeque, Hua, Junjie Tony, Soares, Fraser, Lin, Dong, Puca, Loredana, Vosoughi, Aram, Xue, Hui, Li, Estelle, Su, Peiran, Chen, Sujun, Nguyen, Tran, Liang, Yi, Zhang, Yuzhe, Xu, Xin, Xu, Jing, Sheahan, Anjali V., Ba-Alawi, Wail, Zhang, Si, Mahamud, Osman, Vellanki, Ravi N., Gleave, Martin, Bristow, Robert G., Haibe-Kains, Benjamin, Poirier, John T., Rudin, Charles M., Tsao, Ming-Sound, Wouters, Bradly G., Fazli, Ladan, Feng, Felix Y., Ellis, Leigh, van der Kwast, Theo, Berlin, Alejandro, Koritzinsky, Marianne, Boutros, Paul C., Zoubeidi, Amina, Beltran, Himisha, Wang, Yuzhuo, He, Housheng Hansen · 2019 · Nature Communications

Abstract

Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Clinically, genomically and epigenetically, NEPC resembles other types of poorly differentiated neuroendocrine tumors (NETs). Through pan-NET analyses, we identified ONECUT2 as a candidate master transcriptional regulator of poorly differentiated NETs. ONECUT2 ectopic expression in prostate adenocarcinoma synergizes with hypoxia to suppress androgen signaling and induce neuroendocrine plasticity. ONEUCT2 drives tumor aggressiveness in NEPC, partially through regulating hypoxia signaling and tumor hypoxia. Specifically, ONECUT2 activates SMAD3, which regulates hypoxia signaling through modulating HIF1α chromatin-binding, leading NEPC to exhibit higher degrees of hypoxia compared to prostate adenocarcinomas. Treatment with hypoxia-activated prodrug TH-302 potently reduces NEPC tumor growth. Collectively, these results highlight the synergy between ONECUT2 and hypoxia in driving NEPC, and emphasize the potential of hypoxia-directed therapy for NEPC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-08133-6

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 243

Metadata

Authors
Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., Su, P., Chen, S., Nguyen, T., Liang, Y., Zhang, Y., Xu, X., Xu, J., Sheahan, A. V., Ba-Alawi, W., Zhang, S., Mahamud, O., Vellanki, R. N., Gleave, M., Bristow, R. G., Haibe-Kains, B., Poirier, J. T., Rudin, C. M., Tsao, M.-S., Wouters, B. G., Fazli, L., Feng, F. Y., Ellis, L., van der Kwast, T., Berlin, A., Koritzinsky, M., Boutros, P. C., Zoubeidi, A., Beltran, H., Wang, Y., & He, H. H.
Venue
Nature Communications
Published
2019-01-17
Volume
10
Issue
1
Pages
278-278
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2908623381
Cited by
243
References
8
FWCI
19.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ONECUT2 is a driver of neuroendocrine prostate cancer. https://app.cochat.ai/papers/10.1038/s41467-018-08133-6
The paper
Guo, H., Ci, X., Ahmed, M., Hua, J. T., Soares, F., Lin, D., Puca, L., Vosoughi, A., Xue, H., Li, E., Su, P., Chen, S., Nguyen, T., Liang, Y., Zhang, Y., Xu, X., Xu, J., Sheahan, A. V., Ba-Alawi, W., . . . He, H. H. (2019). ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. https://doi.org/10.1038/s41467-018-08133-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.